Repligen to acquire BioLife for $1.5B enterprise value, $31.00 per share

BIOLIFE SOLUTIONS INC

Repligen to acquire BioLife for $31.00/share (0.1442 RGEN shares + $11.25 cash); total enterprise value ~$1.5B.
Transaction expected to close in Q4 2026, subject to BioLife stockholder approval and regulatory clearances.
BioLife reports preliminary Q2 revenue growth ~21% YoY; Repligen reports preliminary Q2 revenue growth ~12-13% organic.
Deal expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and at least $0.25 in year two.
Termination fee of $59M payable by BioLife under certain circumstances if deal fails.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.